Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ...
AI Sentiment
Positive
7/10
as of 12-02-2025 4:00pm EST
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | LITTLETON |
| Market Cap: | 19.4M | IPO Year: | 2020 |
| Target Price: | $6.75 | AVG Volume (30 days): | 116.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.98 - $7.95 | Next Earning Date: | 11-19-2025 |
| Revenue: | $17,317,000 | Revenue Growth: | 18.76% |
| Revenue Growth (this year): | 19.45% | Revenue Growth (next year): | 70.80% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
VVOS Breaking Stock News: Dive into VVOS Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
7/10
See how VVOS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "VVOS Vivos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.